Lobe Sciences Ltd. (CVE:LOBE) | WebDisclosure

Basculer en Français

11276	Companies
250575	Keywords
179213	Articles
136416	Press releases

Home
Companies
Lobe Sciences Ltd.

PRESS RELEASE

published on 06/18/2025 at 05:58, 1 year 4 months ago

Lobe Sciences Moves Forward with Development of Conjugated Psilocin(TM) Following April 14 Agreement to Spin Out Compound to Cynaptec Pharmaceuticals
Lobe Sciences Ltd. advances Conjugated Psilocin™ research for chronic cluster headaches and addiction via $6M investment in Cynaptec Pharmaceuticals, with option for additional $20M

Clinical Trials Investment Cynaptec Pharmaceuticals Lobe Sciences Ltd. Conjugated Psilocin™
BRIEF

published on 06/03/2025 at 12:15, 1 year 5 months ago

Lobe Sciences Appoints Yong Yao as CFO for Strategic Initiatives

Strategic Growth Operational Expansion Biotech Finance Lobe Sciences Yong Yao
BRIEF

published on 06/03/2025 at 12:15, 1 year 5 months ago

Lobe Sciences nomme Yong Yao au poste de directeur financier des initiatives stratégiques

Croissance Stratégique Expansion Opérationnelle Financement Des Biotechnologies Sciences Du Lobe Yong Yao
PRESS RELEASE

published on 06/03/2025 at 12:10, 1 year 5 months ago

Lobe Sciences Appoints Mr. Yong Yao as Chief Financial Officer to Support Strategic Growth
Lobe Sciences Ltd. appoints Mr. Yong Yao as CFO & EVP, leveraging his 25 years of finance & biotech experience to drive financial strategy & growth. Strategic shift to full-time financial leadership

Chief Financial Officer Executive Vice President Finance Strategy Lobe Sciences Yong Yao
BRIEF

published on 04/14/2025 at 13:05, 1 year 6 months ago

Lobe Sciences Initiates Private Placement for Drug Development

Private Placement Clinical Trials Lobe Sciences Conjugated Psilocin Cynaptec Pharmaceuticals
BRIEF

published on 04/14/2025 at 13:05, 1 year 6 months ago

Lobe Sciences lance un placement privé pour le développement de médicaments

Placement Privé Essais Cliniques Sciences Du Lobe Cynaptec Pharmaceuticals Psilocine Conjuguée
PRESS RELEASE

published on 04/14/2025 at 13:00, 1 year 6 months ago

Lobe Sciences Ltd. Announces Private Placement to Support Drug Development of Novel Conjugated Psilocin(TM)
Lobe Sciences announces US$6M private placement for Cynaptec to fund Conjugated Psilocin development. Option for additional US$20M included. Company focuses on lipid tech for orphan diseases

Private Placement Lobe Sciences Lipid Technology Conjugated Psilocin Cynaptec
BRIEF

published on 04/05/2025 at 05:55, 1 year 6 months ago

Lobe Sciences Provides Corporate Update on Recent Transactions

Clinical Trials Convertible Notes FDA Feedback Lobe Sciences Psilocin Mucate
BRIEF

published on 04/05/2025 at 05:55, 1 year 6 months ago

Lobe Sciences fournit une mise à jour de l'entreprise sur les transactions récentes

Essais Cliniques Billets Convertibles Commentaires De La FDA Sciences Du Lobe Mucate De Psilocine
PRESS RELEASE

published on 04/05/2025 at 05:50, 1 year 6 months ago

Lobe Sciences Provides Corporate Update
Lobe Sciences provides corporate update on recent transactions and business progress including patents and clinical study results. Focus on lipid technology solutions for medical needs

Corporate Update Recent Transactions Lobe Sciences Lipid Technology Medical Needs

Accesswire

Published on 11/04/2026 at 23:10, 46 minutes ago

Ur-Energy Announces Date for Third Quarter 2026 Results and Conference Call and Webcast
Published on 11/04/2026 at 23:00, 56 minutes ago

Avino Reports Q3 2026 Financial Results
Published on 11/04/2026 at 23:00, 56 minutes ago

Viemed Healthcare Announces Third Quarter 2026 Financial Results
Published on 11/04/2026 at 22:15, 1 hour 41 minutes ago

Zomedica Announces Record Third Quarter Revenue of $9.9 Million, Up 22% Year-Over-Year, Net Loss Reduced 48%, with $41 Million in Liquidity
Published on 11/04/2026 at 22:05, 1 hour 51 minutes ago

Stabilis Solutions Announces Third Quarter 2026 Results

View all ACCESSWIRE

EQS Group

Published on 11/04/2026 at 19:41, 4 hours 15 minutes ago

EQS-Adhoc: SNP SE Raises Outlook for the Full Year 2026
Published on 11/04/2026 at 19:25, 4 hours 31 minutes ago

Menarini Group and Ryvu Therapeutics Announce First Clinical Data from the Phase II JASPIS-01 Study of dapolsertib (MEN1703, SEL24) in Heavily Pretreated Relapsed/Refractory Aggressive B-cell non-Hodgkin Lymphoma at the 2026 ASH Annual Meeting
Published on 11/04/2026 at 18:43, 5 hours 13 minutes ago

EQS-Adhoc: Deutsche EuroShop refines its revenue forecast and raises its earnings forecast for the 2026 financial year
Published on 11/04/2026 at 18:05, 5 hours 51 minutes ago

Redis Expands Redis Iris to Give AI Agents the Memory, Context, and Messaging They Need to get to Production
Published on 11/04/2026 at 17:40, 6 hours 16 minutes ago

Carvolix : Nombre d’actions composant le capital social et nombre total de droits de vote au 31.10.26.

Les Echos

Published on 11/04/2026 at 18:00, 5 hours 56 minutes ago

The Belgian State and Engie Group have agreed to extend the target date for concluding the Heads of Terms until 12 December 2026
Published on 11/04/2026 at 18:00, 5 hours 56 minutes ago

L’État belge et le groupe ENGIE ont convenu de se donner un délai supplémentaire jusqu’au 12 décembre 2026 pour la conclusion des Heads of Terms
Published on 11/04/2026 at 17:45, 6 hours 11 minutes ago

October 2026
Published on 11/04/2026 at 17:45, 6 hours 11 minutes ago

Octobre 2026
Published on 11/04/2026 at 17:44, 6 hours 12 minutes ago

Aéroports de Paris SA - Information regarding the voting rights and shares as of 31 October 2026

View all LES ECHOS COMFI WIRE